Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.46 |
| ▸ | NOS1 | P29475 | 6/20 | 0.44 |
| ▸ | NOS2 | P35228 | 6/20 | 0.42 |
| ▸ | NOS3 | P29474 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485480 | 1.00 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL21195165 | 1.00 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL18071127 | 1.00 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL14842600 | 1.00 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL287988 | 1.00 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL9845038 | 0.87 | OTC (0.49) | OTCDDAH1NOS1NOS2NOS3 | |
| SCHEMBL9845041 | 0.87 | OTC (0.49) | OTCDDAH1NOS1NOS2NOS3 | |
| SCHEMBL9845036 | 0.87 | OTC (0.49) | OTCDDAH1NOS1NOS2NOS3 | |
| SCHEMBL18030908 | 0.87 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 | |
| SCHEMBL26431181 | 0.87 | KDM1A (0.51) | KDM1AOTCDDAH1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230151119-A1 | Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023064185-A1 | HOMOGENOUS ENZYME LINKED IMMUNOASSAY | IDEXX LABORATORIES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022148851-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| US-11384158-B2 | Antibodies to symmetrically dimethylated arginine analytes and use thereof | ARK DIAGNOSTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-9458198-B1 | Cyclic peptide-based NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20070224671-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20040220239-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6489308-B1 | ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF | TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | KDM1A 2637/4885OTC 4696/4885DDAH1 1760/4885 |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | KDM1A 2035/4885OTC 608/4885DDAH1 1589/4885 |
| US-11384158-B2 | Antibodies to symmetrically dimethylated arginine analytes and use thereof | PRMT3, PRMT5, PRMT1 | KDM1A 881/4885OTC 418/4885DDAH1 33/4885 |
| US-20230151119-A1 | Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof | PRMT3, PRMT5, PRMT1 | KDM1A 881/4885OTC 418/4885DDAH1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.